EMA and Swissmedic agree on further Cooperation
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The European Medicines Agency (EMA), the Directorate General Health and Food Safety (DG SANTE) of the European Commission and the Swissmedic signed an agreement which aims at ensuring a better exchange of non-public information for the protection of the public health. It is intended to exchange information related to the safety, quality or efficacy of medicines which are either already approved or in the authorisation process in the EU or in Switzerland. A similar agreement existed in 2009/2010 at the time of the H1N1 pandemic. The new agreement has been effective since the 10 July 2015 and will be valid for five years.
To find out more please see the original note on the page of the Swissmedic.
Related GMP News
26.08.2026GMP and "Planned Deviations" - a Contradiction?
19.08.2026Why Root Cause Analysis is the Key to efficient CAPA
19.08.2026EMA updates Guideline on implementing the Shortage Prevention Plan
19.08.2026FDA: Simplified Registration for U.S. Sites and Greater Complexity for Non-U.S. Sites
12.08.2026When Training Fails: FDA Warning Letters Highlight GMP Training Deficiencies in 2026
29.07.2026EU-GMP for Veterinary Medicinal Products: What will change in Switzerland?